Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD4 | Q15561 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | AR | P10275 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16309243 | 0.89 | AR (0.54) | TEAD4ALDH1A1TDP1POLBMAPT | |
| SCHEMBL6807411 | 0.85 | ALDH1A1 (0.52) | TEAD4ALDH1A1TDP1MAPTSMN1; SMN2 | |
| SCHEMBL12386586 | 0.82 | AR (0.49) | ALDH1A1MAPTSMN1; SMN2AR | |
| SCHEMBL7006874 | 0.81 | TTR (0.61) | ALDH1A1ARHSD17B10TRPA1 | |
| SCHEMBL13783391 | 0.81 | TEAD4 (0.61) | TEAD4ALDH1A1TDP1POLBMAPT | |
| SCHEMBL11528953 | 0.81 | TEAD4 (0.61) | TEAD4ALDH1A1TDP1POLBMAPT | |
| SCHEMBL2829833 | 0.81 | ALDH1A1 (0.48) | TEAD4ALDH1A1TDP1MAPTSMN1; SMN2 | |
| SCHEMBL29355313 | 0.81 | TTR (0.61) | ALDH1A1ARHSD17B10TRPA1 | |
| SCHEMBL5607414 | 0.81 | AR (0.46) | ALDH1A1MAPTARTRPA1 | |
| SCHEMBL10292484 | 0.80 | TRPA1 (0.56) | ALDH1A1TDP1POLBMAPTAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3901162-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF | AbbVie Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| US-10668167-B2 | Glucocorticoid receptor agonist and immunoconjugates thereof | ABBVIE INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-20190262465-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF | ABBVIE INC. (US) | 2019-08-29 | — | — | US | disclosed |
| EP-1838300-A2 | 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS | Emergent Product Development Gaithersburg Inc. (US) | 2007-10-03 | — | — | EP | disclosed |
| US-20060211697-A1 | 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG, INC. | 2006-09-21 | — | — | US | disclosed |
| WO-2006071471-A2 | 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10668167-B2 | Glucocorticoid receptor agonist and immunoconjugates thereof | NR3C1, NR3C2, MC2R | TEAD4 3464/4885ALDH1A1 3434/4885TDP1 3874/4885 |
| US-20060211697-A1 | 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents | TYR, NFE2L2, CYP1A1 | TEAD4 242/4885ALDH1A1 1406/4885TDP1 4321/4885 |
| US-20190262465-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF | NR3C1, NR3C2, MC2R | TEAD4 3464/4885ALDH1A1 3434/4885TDP1 3874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.